tenofovir 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definitionDrug idCAS RN
antivirals phosphonic acid derivatives 2592 147127-20-6

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • tenofovir hydrate
  • tenofovir
  • tenefovir
An adenine analog REVERSE TRANSCRIPTASE INHIBITOR with antiviral activity against HIV-1 and HEPATITIS B. It is used to treat HIV INFECTIONS and CHRONIC HEPATITIS B, in combination with other ANTIVIRAL AGENTS, due to the emergence of ANTIVIRAL DRUG RESISTANCE when it is used alone.
  • Molecular weight: 287.22
  • Formula: C9H14N5O4P
  • CLOGP: -1.16
  • LIPINSKI: 0
  • HAC: 9
  • HDO: 3
  • TPSA: 136.38
  • ALOGS: -2.19
  • ROTB: 5

  • Status: OFP

  • Legend:
    OFP - off patent
    OFM - off market
    ONP - on patent

Drug dosage:

None

ADMET properties:

PropertyValueReference
BA (Bioavailability) 25 % Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H
Vd (Volume of distribution) 0.83 L/kg Lombardo F, Berellini G, Obach RS
CL (Clearance) 3.10 mL/min/kg Lombardo F, Berellini G, Obach RS
fu (Fraction unbound in plasma) 0.93 % Lombardo F, Berellini G, Obach RS
t_half (Half-life) 5.80 hours Lombardo F, Berellini G, Obach RS

Approvals:

DateAgencyCompanyOrphan
Nov. 5, 2009 FDA HETERO DRUGS LTD
March 25, 2004 PMDA Japan Tobacco Inc.

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Maternal exposure during pregnancy 198.52 30.95 110 2191 159668 50443155
Drug resistance 138.18 30.95 46 2255 18943 50583880
Rebound effect 130.31 30.95 30 2271 3159 50599664
Virologic failure 110.10 30.95 23 2278 1541 50601282
Drug interaction 102.09 30.95 79 2222 199542 50403281
Foetal exposure during pregnancy 100.39 30.95 40 2261 27319 50575504
Immune reconstitution inflammatory syndrome 95.07 30.95 26 2275 5490 50597333
Fanconi syndrome acquired 91.21 30.95 18 2283 905 50601918
Viral mutation identified 86.55 30.95 19 2282 1610 50601213
Exposure during pregnancy 82.34 30.95 57 2244 120958 50481865
Hepatitis B 72.29 30.95 19 2282 3447 50599376
Premature delivery 54.84 30.95 25 2276 23638 50579185
Pathogen resistance 54.47 30.95 17 2284 5672 50597151
Birth mark 49.23 30.95 8 2293 130 50602693
Congenital umbilical hernia 49.08 30.95 9 2292 304 50602519
Fanconi syndrome 48.05 30.95 11 2290 1125 50601698
Abortion spontaneous 46.70 30.95 27 2274 41745 50561078
Blood HIV RNA increased 44.03 30.95 9 2292 540 50602283
Immune reconstitution inflammatory syndrome associated tuberculosis 42.21 30.95 8 2293 324 50602499
Autoimmune hepatitis 42.11 30.95 15 2286 7504 50595319
Renal tubular dysfunction 41.28 30.95 8 2293 365 50602458
Hypophosphataemic osteomalacia 40.64 30.95 7 2294 164 50602659
Glycosuria 37.85 30.95 9 2292 1085 50601738
Ergot poisoning 37.06 30.95 6 2295 95 50602728
Glucocorticoids increased 35.46 30.95 6 2295 126 50602697
Stillbirth 33.80 30.95 12 2289 5940 50596883
Treatment noncompliance 32.39 30.95 19 2282 30131 50572692
Abortion induced 31.93 30.95 13 2288 9331 50593492
Hereditary optic atrophy 30.99 30.95 4 2297 10 50602813

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Immune reconstitution inflammatory syndrome 227.71 22.88 73 4536 7729 29562189
Psychiatric decompensation 150.66 22.88 37 4572 1467 29568451
Retinal toxicity 149.00 22.88 29 4580 375 29569543
Depression suicidal 145.25 22.88 35 4574 1280 29568638
Mitochondrial toxicity 137.96 22.88 38 4571 2373 29567545
Tearfulness 137.66 22.88 35 4574 1601 29568317
Lipodystrophy acquired 137.39 22.88 40 4569 3054 29566864
Progressive external ophthalmoplegia 134.96 22.88 33 4576 1284 29568634
Drug interaction 123.22 22.88 152 4457 197233 29372685
Acquired gene mutation 121.21 22.88 30 4579 1228 29568690
Hepatitis B 118.63 22.88 41 4568 5456 29564462
Fanconi syndrome acquired 100.62 22.88 28 4581 1814 29568104
Eyelid ptosis 90.33 22.88 33 4576 5153 29564765
Foetal exposure during pregnancy 86.60 22.88 58 4551 33809 29536109
Depressive symptom 84.24 22.88 24 4585 1693 29568225
Drug resistance 83.26 22.88 48 4561 21492 29548426
Paranoia 79.15 22.88 36 4573 9841 29560077
Psychomotor skills impaired 77.96 22.88 25 4584 2636 29567282
Pathogen resistance 76.01 22.88 33 4576 8083 29561835
Psychotic disorder 72.44 22.88 43 4566 20311 29549607
Hepatic failure 71.16 22.88 50 4559 31462 29538456
Diplopia 62.78 22.88 34 4575 13484 29556434
Gene mutation 62.28 22.88 17 4592 1024 29568894
Ophthalmoplegia 50.07 22.88 16 4593 1666 29568252
Hepatitis B reactivation 46.92 22.88 18 4591 3211 29566707
Suicidal ideation 45.56 22.88 40 4569 34676 29535242
Congenital umbilical hernia 43.95 22.88 10 4599 283 29569635
Birth mark 43.54 22.88 9 4600 160 29569758
Drug-induced liver injury 43.45 22.88 32 4577 21623 29548295
Adrenal suppression 42.86 22.88 11 4598 521 29569397
Night blindness 41.14 22.88 9 4600 212 29569706
Psychomotor retardation 37.63 22.88 15 4594 2961 29566957
Superior mesenteric artery syndrome 37.51 22.88 7 4602 71 29569847
Nephropathy toxic 36.36 22.88 22 4587 10734 29559184
BRASH syndrome 32.62 22.88 7 4602 150 29569768
Fanconi syndrome 30.93 22.88 11 4598 1587 29568331
Mitochondrial myopathy 30.80 22.88 7 4602 197 29569721
Hepatocellular carcinoma 30.72 22.88 17 4592 7021 29562897
Anxiety 29.65 22.88 50 4559 85315 29484603
Osteomalacia 28.84 22.88 9 4600 867 29569051
Renal tubular dysfunction 25.89 22.88 7 4602 406 29569512
Portal hypertension 25.70 22.88 12 4597 3474 29566444
Brachydactyly 25.57 22.88 6 4603 195 29569723
Osteoporotic fracture 23.74 22.88 8 4601 983 29568935
Hepatic fibrosis 23.37 22.88 11 4598 3241 29566677
Depression 23.33 22.88 45 4564 85102 29484816

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Immune reconstitution inflammatory syndrome 340.42 20.91 100 6352 12370 64479910
Hepatitis B 202.02 20.91 60 6392 7685 64484595
Drug interaction 188.81 20.91 205 6247 361878 64130402
Drug resistance 158.52 20.91 75 6377 35027 64457253
Progressive external ophthalmoplegia 149.24 20.91 33 6419 1294 64490986
Retinal toxicity 149.17 20.91 33 6419 1297 64490983
Psychiatric decompensation 148.79 20.91 37 6415 2426 64489854
Mitochondrial toxicity 145.33 20.91 37 6415 2669 64489611
Fanconi syndrome acquired 144.40 20.91 36 6416 2385 64489895
Depression suicidal 138.64 20.91 35 6417 2440 64489840
Acquired gene mutation 136.00 20.91 33 6419 1953 64490327
Pathogen resistance 135.70 20.91 50 6402 12493 64479787
Lipodystrophy acquired 135.29 20.91 38 6414 3989 64488291
Maternal exposure during pregnancy 119.35 20.91 89 6363 95795 64396485
Tearfulness 116.61 20.91 35 6417 4638 64487642
Rebound effect 102.18 20.91 32 6420 4885 64487395
Viral mutation identified 87.55 20.91 26 6426 3320 64488960
Eyelid ptosis 81.48 20.91 32 6420 9493 64482787
Psychomotor skills impaired 79.79 20.91 25 6427 3820 64488460
Paranoia 77.02 20.91 36 6416 16316 64475964
Fanconi syndrome 76.77 20.91 22 6430 2479 64489801
Psychotic disorder 76.63 20.91 46 6406 34532 64457748
Depressive symptom 75.95 20.91 25 6427 4471 64487809
Gene mutation 71.53 20.91 20 6432 2062 64490218
Hepatitis B reactivation 69.97 20.91 24 6428 4865 64487415
Hepatic failure 65.69 20.91 50 6402 55344 64436936
Virologic failure 61.48 20.91 20 6432 3446 64488834
Nephropathy toxic 57.03 20.91 30 6422 17484 64474796
CSF HIV escape syndrome 53.11 20.91 11 6441 314 64491966
Diplopia 52.63 20.91 33 6419 26732 64465548
Drug-induced liver injury 52.10 20.91 41 6411 47602 64444678
Adrenal suppression 46.74 20.91 13 6439 1314 64490966
Ophthalmoplegia 45.53 20.91 15 6437 2687 64489593
Night blindness 43.98 20.91 10 6442 445 64491835
Glycosuria 41.01 20.91 13 6439 2061 64490219
Renal tubular dysfunction 39.69 20.91 10 6442 690 64491590
Psychomotor retardation 39.53 20.91 16 6436 5127 64487153
Hypophosphataemia 39.00 20.91 22 6430 14698 64477582
Immune reconstitution inflammatory syndrome associated tuberculosis 38.71 20.91 10 6442 763 64491517
Suicidal ideation 38.48 20.91 40 6412 66502 64425778
Blood HIV RNA increased 36.52 20.91 11 6441 1473 64490807
Superior mesenteric artery syndrome 35.20 20.91 7 6445 162 64492118
Hepatocellular carcinoma 34.98 20.91 17 6435 8386 64483894
Exposure during pregnancy 33.40 20.91 40 6412 77635 64414645
Osteomalacia 32.90 20.91 10 6442 1381 64490899
Hepatic encephalopathy 31.74 20.91 22 6430 21044 64471236
Mitochondrial myopathy 31.46 20.91 7 6445 282 64491998
Foetal exposure during pregnancy 31.25 20.91 13 6439 4463 64487817
Hypophosphataemic osteomalacia 31.13 20.91 7 6445 296 64491984
Hereditary optic atrophy 31.05 20.91 5 6447 32 64492248
Glucocorticoids increased 30.73 20.91 6 6446 126 64492154
Ergot poisoning 30.29 20.91 6 6446 136 64492144
Portal hypertension 30.23 20.91 14 6438 6205 64486075
BRASH syndrome 29.61 20.91 7 6445 370 64491910
Hepatic cirrhosis 29.53 20.91 23 6429 26275 64466005
Renal impairment 26.47 20.91 48 6404 134969 64357311
Renal tubular necrosis 26.28 20.91 20 6432 22090 64470190
Meningitis cryptococcal 25.34 20.91 10 6442 2999 64489281
Treatment noncompliance 24.87 20.91 26 6426 43456 64448824
Premature delivery 24.74 20.91 18 6434 18571 64473709
Autoimmune hepatitis 23.85 20.91 14 6438 10070 64482210
Unmasking of previously unidentified disease 23.23 20.91 8 6444 1639 64490641
HIV infection 22.97 20.91 7 6445 975 64491305
Cerebral toxoplasmosis 22.42 20.91 8 6444 1818 64490462
Hepatic fibrosis 22.41 20.91 11 6441 5541 64486739
Malaise 22.40 20.91 6 6446 396241 64096039
Abortion spontaneous 21.96 20.91 19 6433 25124 64467156
Cushingoid 21.87 20.91 12 6440 7591 64484689
Oligohydramnios 21.56 20.91 9 6443 3115 64489165
Acute hepatic failure 21.34 20.91 19 6433 26093 64466187
Abortion induced 20.95 20.91 11 6441 6377 64485903
Vascular stent thrombosis 20.92 20.91 9 6443 3355 64488925

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

SourceCodeDescription
MeSH PA D019380 Anti-HIV Agents
MeSH PA D000890 Anti-Infective Agents
MeSH PA D044966 Anti-Retroviral Agents
MeSH PA D000998 Antiviral Agents
MeSH PA D004791 Enzyme Inhibitors
MeSH PA D019384 Nucleic Acid Synthesis Inhibitors
MeSH PA D018894 Reverse Transcriptase Inhibitors
CHEBI has role CHEBI:36044 antiviral drugs
CHEBI has role CHEBI:49103 drug metabolites
CHEBI has role CHEBI:53756 reverse transcriptase inhibitors

Drug Use | Suggest Off label Use Form| |View source of the data|

DiseaseRelationSNOMED_IDDOID
Chronic type B viral hepatitis indication 61977001
Human immunodeficiency virus infection indication 86406008 DOID:526
Coronavirus infection off-label use 186747009
Prevention of HIV Infection after Exposure off-label use
Osteomalacia contraindication 4598005 DOID:10573
Hypophosphatemia contraindication 4996001
Suicidal thoughts contraindication 6471006
Hypercholesterolemia contraindication 13644009
Torsades de pointes contraindication 31722008
Depressive disorder contraindication 35489007
Fanconi syndrome contraindication 40488004 DOID:1062
Acute nephropathy contraindication 58574008
Hepatic failure contraindication 59927004
Aggressive behavior contraindication 61372001
Kidney disease contraindication 90708001 DOID:557
Lactic acidosis contraindication 91273001 DOID:3650
Prolonged QT interval contraindication 111975006
Chronic hepatitis C contraindication 128302006
Seizure disorder contraindication 128613002
Liver function tests abnormal contraindication 166603001
Paranoid disorder contraindication 191667009
Steatosis of liver contraindication 197321007
Mania contraindication 231494001
Disease of liver contraindication 235856003 DOID:409
Pathological fracture contraindication 268029009
Pregnancy, function contraindication 289908002
Hypertriglyceridemia contraindication 302870006
Severe depression contraindication 310497006
Osteopenia contraindication 312894000
Breastfeeding (mother) contraindication 413712001
Obesity contraindication 414916001 DOID:9970
Congenital long QT syndrome contraindication 442917000




🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 0.23 acidic
pKa2 4.92 acidic
pKa3 4.28 Basic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])
Mechanism
action
Bioact sourceMoA source
Reverse transcriptase/RNaseH Enzyme IC50 6.42 CHEMBL
Reverse transcriptase Enzyme IC50 6.42 CHEMBL
Capsid protein Unclassified EC50 6.62 CHEMBL

External reference:

IDSource
4021279 VUID
N0000148716 NUI
D06074 KEGG_DRUG
4021279 VANDF
C0384228 UMLSCUI
CHEBI:63625 CHEBI
TFO PDB_CHEM_ID
CHEMBL483 ChEMBL_ID
CHEMBL3989702 ChEMBL_ID
CHEMBL1486 ChEMBL_ID
DB14126 DRUGBANK_ID
D000068698 MESH_DESCRIPTOR_UI
464205 PUBCHEM_CID
10948 IUPHAR_LIGAND_ID
99YXE507IL UNII
117466 RXNORM
d04774 MMSL
009357 NDDF
395264002 SNOMEDCT_US
422091007 SNOMEDCT_US
206184-49-8 SECONDARY_CAS_RN

Pharmaceutical products:

None